Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
AstraZeneca's VOLGA Phase 3 trial showed perioperative IMFINZI plus neoadjuvant enfortumab vedotin cut risk of recurrence, progression or death by 49% and risk of death by 42% in cisplatin-ineligible muscle-invasive bladder cancer. At two years, 64% of patients on the combination were alive and event-free versus 45% with standard of care, and 78% were alive versus 69%; safety was consistent with the known profiles of both drugs.
Key figures
- Drug Name
- IMFINZI (durvalumab)
- Phase Of Trial
- Phase 3
- Os p value
- 0.0027
- Efs p value
- <0.0001
- Trial centers
- 182
- Os hazard ratio
- 0.58
- Trial countries
- 25
- Efs hazard ratio
- 0.51
- Os risk reduction
- 42%
- Efs risk reduction
- 49%
- Patients randomized
- 695
- Os rate 24mo treatment
- 78%
- Efs rate 24mo treatment
- 64%
- Os rate 24mo comparator
- 69%
- Efs rate 24mo comparator
- 45%
- Comparator median efs months
- 12.1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.